Literature DB >> 11459289

Growth inhibition and apoptosis induced by P2Y2 receptors in human colorectal carcinoma cells: involvement of intracellular calcium and cyclic adenosine monophosphate.

M Höpfner1, K Maaser, B Barthel, B von Lampe, C Hanski, E O Riecken, M Zeitz, H Scherübl.   

Abstract

Extracellular nucleotides induce apoptosis and inhibit growth of colorectal cancer cells. To understand the underlying signaling pathways, we investigated the role of nucleotide-sensitive P2 receptors and focused on the receptor-mediated signaling of intracellular Ca2+ and cyclic adenosine monophosphate (cAMP) in two colorectal carcinoma cell lines (HT29, Colo320 DM). Expression and functionality of P2 receptor subtypes evaluated by RT-PCR and [Ca2+]i imaging revealed that solely metabotropic P2 receptors of the subtype P2Y2 were expressed on a functional level in both cell lines. Short-term stimulation of P2Y2 receptors caused Ca2+ mobilization from intracellular stores and a subsequent transmembrane Ca2+ influx. The receptor-induced [Ca2+]i elevation was shown to increase basal-stimulated [cAMP]i moderately and to potentiate forskolin-stimulated [cAMP]i vigorously, since the effects were dose-dependently inhibited by preloading the cells with the [Ca2+]i chelator BAPTA. In contrast, activation of protein kinase C (PKC) did not contribute to a receptor-mediated rise in [cAMP]i, since the PKC inhibitor staurosporine completely failed to reduce P2Y2 receptor-induced increases in [cAMP]i. Prolonged application of P2Y2 receptor agonists induced a time-dependent increase in apoptosis (up to 50% above control values) in both cell lines and caused dose-dependent inhibition of cell proliferation of up to 85% (Colo320 DM) or 64% (HT29). Chelating [Ca2+]i with BAPTA almost completely abolished P2Y2 receptor-induced cell death. Rises in [cAMP]i elicited by either forskolin or cAMP derivatives inhibited growth in both cell lines, too. In line with the potentiating effect of P2Y2 receptors on forskolin-stimulated [cAMP]i increases, costimulation with forskolin and P2Y2 receptor agonists led to synergistic antiproliferative effects. Moreover, a synergistic growth inhibition was observed when coincubating the cells with the P2Y2 receptor agonist ATP and the cytostatic drug 5-fluorouracil, which forms the basis for most currently applied chemotherapeutic regimes in colorectal cancer treatment. Our results demonstrate the growth inhibitory potency of P2Y2 receptors in colorectal carcinoma cells. Receptor-induced [Ca2+]i signaling appears to play a major role in the observed antiproliferative and apoptosis-inducing effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459289     DOI: 10.1007/s003840100302

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  22 in total

1.  Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer.

Authors:  Beat M Künzli; Maria-Isabell Bernlochner; Stephan Rath; Samuel Käser; Eva Csizmadia; Keiichi Enjyoji; Peter Cowan; Anthony d'Apice; Karen Dwyer; Robert Rosenberg; Aurel Perren; Helmut Friess; Christoph A Maurer; Simon C Robson
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

2.  Reviewing the role of P2Y receptors in specific gastrointestinal cancers.

Authors:  Steve Dagenais Bellefeuille; Caroline M Molle; Fernand-Pierre Gendron
Journal:  Purinergic Signal       Date:  2019-09-02       Impact factor: 3.765

3.  Inhibitory effects of extracellular adenosine triphosphate on growth of esophageal carcinoma cells.

Authors:  Ming-Xia Wang; Lei-Ming Ren; Bao-En Shan
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

4.  Effect of extracellular ATP on the human leukaemic cell line K562 and its multidrug counterpart.

Authors:  Alcira A Bernardo; Flavio Eduardo Pinto-Silva; Pedro M Persechini; Robson Coutinho-Silva; José Roberto Meyer-Fernandes; André Luiz Fonseca de Souza; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2006-07-06       Impact factor: 3.396

Review 5.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

6.  Purinergic receptor antagonism prevents cold preservation-induced cell death independent of cellular ATP levels.

Authors:  Christopher D Anderson; Janene Pierce; Ian B Nicoud; Andrey E Belous; Christopher M Jones; Ravi S Chari
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

7.  Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.

Authors:  Magis Mandapathil; Miroslaw J Szczepanski; Marta Szajnik; Jin Ren; Diana E Lenzner; Edwin K Jackson; Elieser Gorelik; Stephan Lang; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

Review 8.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

Review 9.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

10.  A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine.

Authors:  Michael Höpfner; Andreas P Sutter; Alexander Huether; Gudrun Ahnert-Hilger; Hans Scherübl
Journal:  BMC Cancer       Date:  2004-05-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.